AIMMUNE THERAPEUTICS INC - COM (AIMT)

CUSIP: 00900T107

Q3 2019 13F Holders as of 30 Sep 2019

Type / Class
Equity / COM
Total 13F shares
52,031,455
Share change
+2,804,437
Total reported value
$1,089,570,102
Put/Call ratio
130%
Price per share
$20.94
Number of holders
142
Value change
+$59,135,623
Number of buys
91
Number of sells
47

Quarterly Holders Quick Answers

What is CUSIP 00900T107?
CUSIP 00900T107 identifies AIMT - AIMMUNE THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q3 2019

As of 30 Sep 2019, AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by 142 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 52,031,455 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, BlackRock Inc., Palo Alto Investors LP, EVENTIDE ASSET MANAGEMENT, LLC, WELLINGTON MANAGEMENT GROUP LLP, Foresite Capital Management II, LLC, FMR LLC, ALLIANCEBERNSTEIN L.P., and STATE STREET CORP. This page lists 142 institutional shareholders reporting positions in this security for the Q3 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.